Sarcoma of cervix uteri

Sarcoma of the cervix uteri is an extremely rare malignant tumor arising from the mesenchymal (connective) tissues of the uterine cervix. Unlike the more common cervical carcinomas, which originate from epithelial cells, cervical sarcomas develop from the stromal, smooth muscle, or other supportive tissues of the cervix. This group of tumors includes several histological subtypes such as leiomyosarcoma, endometrial stromal sarcoma, rhabdomyosarcoma (particularly embryonal rhabdomyosarcoma or sarcoma botryoides in younger patients), adenosarcoma, and undifferentiated sarcomas. Due to their rarity, these tumors account for less than 1% of all cervical malignancies. Clinical presentation typically includes abnormal vaginal bleeding (which may be postmenopausal, intermenstrual, or postcoital), a cervical mass or polyp, pelvic pain, and vaginal discharge. In some cases, a protruding grape-like mass may be visible, particularly in the botryoid variant seen in children and young women. The disease primarily affects the reproductive system but can spread locally to surrounding pelvic structures and distantly to the lungs, liver, and other organs. Due to the rarity of cervical sarcomas, there are no standardized treatment protocols, and management is largely extrapolated from experience with uterine sarcomas and other soft tissue sarcomas. Treatment typically involves radical surgical resection, often including hysterectomy with or without pelvic lymph node dissection. Adjuvant chemotherapy and/or radiation therapy may be considered depending on the histological subtype, stage, and completeness of surgical resection. Prognosis varies significantly by subtype and stage at diagnosis, but overall outcomes tend to be less favorable compared to cervical carcinomas. Multidisciplinary care at specialized centers is strongly recommended.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Sarcoma of cervix uteri